Pharmacotherapy Practice Patterns and Outcomes in Bronchiolitis in the Americas, Australia/New Zealand and Europe

Although bronchiolitis has been a long-standing target of research, there is lack of conclusive evidence of benefit for pharmacotherapeutic management in changing the course of the disease. Bronchiolitis management guidelines and clinical reviews advocate the use of supportive measures only and advise against routine use of all pharmacotherapeutic agents in the emergency department (ED) setting. Despite this, preliminary evidence suggests wide practice variation of bronchiolitis management around the world. The Paediatric Emergency Research Networks (PERN) bronchiolitis study will take place in a multi-continent context to study the treatment of infants with bronchiolitis in different corners of the world.  It will collect data to explore if babies receiving medications fare any differently than their counterparts managed only supportively.

Study design

Multi-centre retrospective cohort study

Chief Investigator

Suzanne Schuh (Toronto, Canada), Stuart Dalziel (PREDICT, NZ)

Time frame

2014 – 2015



Site locations

  • Starship Children’s Hospital, Auckland, New Zealand
  • Kidz First Middlemore Hospital, Auckland, New Zealand
  • Royal Children’s Hospital, Melbourne, Australia
  • Monash Children’s Hospital, Victoria, Australia.
  • Townsville Hospital, Townsville, Queensland, Australia.
  • Sunshine Hospital, Melbourne, Australia.
  • Princess Margaret Hospital, Perth, Australia.
  • Women’s and Children’s Hospital, Adelaide, Australia
  • Sydney Children’s Hospital, Randwick, Sydney, Australia
  • Mater Children’s Hospital, Brisbane, Australia.


Approximately 3000 children aged (Jan 2012 – Dec 2013)